{"filing":{"accession_number":"0001193125-26-429549","cik":"0001861123","ticker":"EIKN","company_name":"Eikon Therapeutics, Inc.","form":"8-K","filing_date":"2026-10-23","report_date":"2026-10-23","primary_document":"eikn-20261023.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526429549/eikn-20261023.htm"},"events":[{"id":37478,"run_id":34546,"accession_number":"0001193125-26-429549","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Eikon disclosed clinical trial data for three drug candidates (EIK1003, EIK1004, EIK1005) presented at the 2026 ESMO Congress, including Phase 1/2 safety and efficacy results, objective response rates, adverse event profiles, and dose-escalation findings across multiple cohorts and combination strategies.","company_name":"Eikon Therapeutics, Inc.","ticker":"EIKN","filing_date":"2026-10-23","form":"8-K","submitted_at":null,"items":[{"id":42204,"accession_number":"0001193125-26-429549","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Eikon disclosed clinical trial data for three drug candidates (EIK1003, EIK1004, EIK1005) presented at the 2026 ESMO Congress. This is a material operational/clinical milestone for a late-stage biopharmaceutical company, as the data supports continued development of its pipeline programs and demonstrates safety and efficacy signals across multiple cohorts and combination strategies. While not a specific named event type, this clinical data disclosure is clearly material to investors assessing the company's pipeline progress and drug development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T13:16:40.742675+00:00","company_name":"","ticker":null,"filing_date":""},{"id":42205,"accession_number":"0001193125-26-429549","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This Item 8.01 discloses presentation of clinical trial data for three drug candidates (EIK1003, EIK1004, EIK1005) at the 2026 ESMO Congress. The disclosure includes detailed safety and efficacy results from Phase 1/2 trials, including objective response rates, adverse event profiles, and dose-escalation findings. While this is a clinical milestone event typical for biopharmaceutical companies, it does not fit neatly into the specific event categories (e.g., not an earnings release, not an M\u0026A event, not a restatement). The data presentation represents a material operational/clinical development milestone that would inform investors about pipeline progress and drug candidate viability, making it material to a reasonable investor's assessment of the company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T13:16:40.742675+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42204,"accession_number":"0001193125-26-429549","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Eikon disclosed clinical trial data for three drug candidates (EIK1003, EIK1004, EIK1005) presented at the 2026 ESMO Congress. This is a material operational/clinical milestone for a late-stage biopharmaceutical company, as the data supports continued development of its pipeline programs and demonstrates safety and efficacy signals across multiple cohorts and combination strategies. While not a specific named event type, this clinical data disclosure is clearly material to investors assessing the company's pipeline progress and drug development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T13:16:40.742675+00:00","company_name":"Eikon Therapeutics, Inc.","ticker":"EIKN","filing_date":"2026-10-23"},{"id":42205,"accession_number":"0001193125-26-429549","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This Item 8.01 discloses presentation of clinical trial data for three drug candidates (EIK1003, EIK1004, EIK1005) at the 2026 ESMO Congress. The disclosure includes detailed safety and efficacy results from Phase 1/2 trials, including objective response rates, adverse event profiles, and dose-escalation findings. While this is a clinical milestone event typical for biopharmaceutical companies, it does not fit neatly into the specific event categories (e.g., not an earnings release, not an M\u0026A event, not a restatement). The data presentation represents a material operational/clinical development milestone that would inform investors about pipeline progress and drug candidate viability, making it material to a reasonable investor's assessment of the company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T13:16:40.742675+00:00","company_name":"Eikon Therapeutics, Inc.","ticker":"EIKN","filing_date":"2026-10-23"}]}